The following represents disclosure information provided by authors of this abstract. The program committee has reviewed all presenting author disclosure reports, identified potential conflicts of interest, and implemented strategies to manage those areas of conflict, where appropriate. All relationships are considered compensated. Relationships are self-held unless otherwise noted. I = Immediate Family Member, Inst = My Institution
 
Open Payments is a public database containing information reported by companies about payments made to US-licensed physicians (Open Payments)
A retrospective multicenter study evaluating the efficacy and safety of irinotecan in patients with advanced gastric cancer: Analysis of albumin-bilirubin (ALBI) grade.
 
Iori Motoo
No Relationships to Disclose
 
Yoshito Komatsu
Honoraria - Asahi Kasei; Asahi Kasei; Asahi Kasei; Asahi Kasei; Bayer Yakuhin; Bayer Yakuhin; Bayer Yakuhin; Bayer Yakuhin; Bristol-Myers Squibb; Bristol-Myers Squibb; Bristol-Myers Squibb; Bristol-Myers Squibb; Chugai Pharma; Chugai Pharma; Chugai Pharma; Chugai Pharma; Lilly; Lilly; Lilly; Lilly; Medical Review Co., Ltd.; Medical Review Co., Ltd.; Medical Review Co., Ltd.; Medical Review Co., Ltd.; Merck; Merck; Merck; Merck; Mitsubishi Tanabe Pharma; Mitsubishi Tanabe Pharma; Mitsubishi Tanabe Pharma; Mitsubishi Tanabe Pharma; Moroo Co.; Moroo Co.; Moroo Co.; Moroo Co.; Nipro Corporation; Nipro Corporation; Nipro Corporation; Nipro Corporation; Ono Pharmaceutical; Ono Pharmaceutical; Ono Pharmaceutical; Ono Pharmaceutical; Otsuka; Otsuka; Otsuka; Otsuka; Sanofi/Aventis; Sanofi/Aventis; Sanofi/Aventis; Sanofi/Aventis; Shiseido; Shiseido; Shiseido; Shiseido; Taiho Pharmaceutical; Taiho Pharmaceutical; Taiho Pharmaceutical; Taiho Pharmaceutical; Takeda; Takeda; Takeda; Takeda; Yakult Honsha; Yakult Honsha; Yakult Honsha; Yakult Honsha
Research Funding - A2 Healthcare; A2 Healthcare; A2 Healthcare; A2 Healthcare; Astellas Pharma; Astellas Pharma; Astellas Pharma; Astellas Pharma; Bayer Yakuhin; Bayer Yakuhin; Bayer Yakuhin; Bayer Yakuhin; Daiichi Sankyo; Daiichi Sankyo; Daiichi Sankyo; Daiichi Sankyo; Eisai; Eisai; Eisai; Eisai; Incyte; Incyte; Incyte; Incyte; IQvia; IQvia; IQvia; IQvia; Mediscience Planning; Mediscience Planning; Mediscience Planning; Mediscience Planning; Merck Sharp & Dohme; Merck Sharp & Dohme; Merck Sharp & Dohme; Merck Sharp & Dohme; NanoCarrier; NanoCarrier; NanoCarrier; NanoCarrier; Ono Pharmaceutical; Ono Pharmaceutical; Ono Pharmaceutical; Ono Pharmaceutical; Parexel International Corporation.; Parexel International Corporation.; Parexel International Corporation.; Parexel International Corporation.; Sanofi/Aventis; Sanofi/Aventis; Sanofi/Aventis; Sanofi/Aventis; Shionogi; Shionogi; Shionogi; Shionogi; Sumitomo Dainippon; Sumitomo Dainippon; Sumitomo Dainippon; Sumitomo Dainippon; Sysmex; Sysmex; Sysmex; Sysmex; Taiho Pharmaceutical; Taiho Pharmaceutical; Taiho Pharmaceutical; Taiho Pharmaceutical; Yakult Honsha; Yakult Honsha; Yakult Honsha; Yakult Honsha
 
Satoshi Yuki
Honoraria - Bayer Yakuhin; Bayer Yakuhin; Bayer Yakuhin; Bayer Yakuhin; Bristol-Myers Squibb Japan; Bristol-Myers Squibb Japan; Bristol-Myers Squibb Japan; Bristol-Myers Squibb Japan; Chugai Pharma; Chugai Pharma; Chugai Pharma; Chugai Pharma; Lilly Japan; Lilly Japan; Lilly Japan; Lilly Japan; Merck Serono; Merck Serono; Merck Serono; Merck Serono; Ono Pharmaceutical; Ono Pharmaceutical; Ono Pharmaceutical; Ono Pharmaceutical; Sanofi; Sanofi; Sanofi; Sanofi; Taiho Pharmaceutical; Taiho Pharmaceutical; Taiho Pharmaceutical; Taiho Pharmaceutical; Takeda; Takeda; Takeda; Takeda; Yakult Honsha; Yakult Honsha; Yakult Honsha; Yakult Honsha
 
Shintaro Nakano
No Relationships to Disclose
 
Hiroshi Nakatsumi
Honoraria - Bayer Yakuhin; Bayer Yakuhin; Bayer Yakuhin; Bayer Yakuhin; Chugai Pharma; Chugai Pharma; Chugai Pharma; Chugai Pharma; Lilly Japan; Lilly Japan; Lilly Japan; Lilly Japan; Ono Pharmaceutical; Ono Pharmaceutical; Ono Pharmaceutical; Ono Pharmaceutical; Takeda; Takeda; Takeda; Takeda
 
Yasuyuki Kawamoto
Honoraria - Chugai Pharma; Chugai Pharma; Chugai Pharma; Chugai Pharma; Kyowa Hakko Kirin; Kyowa Hakko Kirin; Kyowa Hakko Kirin; Kyowa Hakko Kirin; Merck Serono; Merck Serono; Merck Serono; Merck Serono; Taiho Pharmaceutical; Taiho Pharmaceutical; Taiho Pharmaceutical; Taiho Pharmaceutical; Takeda; Takeda; Takeda; Takeda
Research Funding - Japan Agency for Medical Research and Development; Japan Agency for Medical Research and Development; Japan Agency for Medical Research and Development; Japan Agency for Medical Research and Development
 
Tetsuhito Muranaka
No Relationships to Disclose
 
Kentaro Sawada
No Relationships to Disclose
 
Takayuki Ando
Speakers' Bureau - Lilly Japan; Lilly Japan; Lilly Japan; Lilly Japan; Taiho Pharmaceutical; Taiho Pharmaceutical; Taiho Pharmaceutical; Taiho Pharmaceutical
 
Takuto Miyagishima
No Relationships to Disclose
 
Kazuaki Harada
No Relationships to Disclose
 
Yoshimitsu Kobayashi
No Relationships to Disclose
 
Kazuteru Hatanaka
No Relationships to Disclose
 
Atsushi Ishiguro
No Relationships to Disclose
 
Aya Tanimoto
No Relationships to Disclose
 
Takuya Honda
No Relationships to Disclose
 
Masayoshi Dazai
No Relationships to Disclose
 
Takahide Sasaki
No Relationships to Disclose
 
Naoya Sakamoto
No Relationships to Disclose